SCHEMBL2190190

SCHEMBL2190190

[SiH3]OC(c1ccccc1)(c1ccccc1)[C@@H]1CCCN1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.57
CYP1A2 P05177 3/20 0.57
CYP2C19 P33261 2/20 0.57
KDM4E B2RXH2 1/20 0.57
NPC1 O15118 1/20 0.57
HPGD P15428 1/20 0.57
MAPK1 P28482 1/20 0.57
RAB9A P51151 1/20 0.57
TACR1 P25103 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
TP53 P04637 2/20 0.36
CYP3A4 P08684 2/20 0.36
TSHR P16473 2/20 0.36
MAPT P10636 1/20 0.36
CYP2C9 P11712 1/20 0.36
THPO P40225 1/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 2/20 0.36
GMNN O75496 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10327286 0.83 CYP1A2 (0.57) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL23791026 0.83 CYP2D6 (0.57) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL2576834 0.83 CYP1A2 (0.57) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL10326847 0.83 CYP1A2 (0.57) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL1447193 0.80 CYP2D6 (0.56) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL2574515 0.80 CYP2D6 (0.56) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL12410019 0.80 CYP1A2 (0.53) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL3004482 0.80 CYP2D6 (0.56) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL23480058 0.80 CYP2D6 (0.53) CYP2D6CYP1A2CYP2C19KDM4ENPC1
SCHEMBL18943754 0.80 CYP1A2 (0.53) CYP2D6CYP1A2CYP2C19KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11512041-B2 Highly enantioselective access to cyclic beta-amino acids NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2022-11-29 US disclosed
US-20210171436-A1 HIGHLY ENANTIOSELECTIVE ACCESS TO CYCLIC BETA-AMINO ACIDS UNIV NANYANG TECH (SG) 2021-06-10 US disclosed
EP-3599246-A1 MEANS AND METHODS FOR SYNTHESIZING PRECURSORS OF Y-AMINOBUTYRIC ACID (GABA) ANALOGS RIJKSUNIVERSITEIT GRONINGEN (NL) 2020-01-29 EP disclosed
US-9593071-B2 Process for the preparation of gamma amino acids and intermediates used in said process ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) 2017-03-14 US disclosed
US-20160229778-A1 DIRECT B-ARYLATION OF CARBONYL COMPOUNDS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2016-08-11 US disclosed
EP-2703381-B1 METHOD FOR PRODUCING FIVE-MEMBERED RING-CONTAINING COMPOUND ONO PHARMACEUTICAL CO (JP) 2015-10-21 EP disclosed
CN-104220433-A Process for preparing gamma amino acids and intermediates useful in said process ROYAL COLLEGE OF SURGEONS IE 2014-12-17 CN disclosed
US-20140336412-A1 PROCESS FOR THE PREPARATION OF GAMMA AMINO ACIDS AND INTERMEDIATES USED IN SAID PROCESS ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) 2014-11-13 US disclosed
EP-2782911-A1 PROCESS FOR THE PREPARATION OF GAMMA AMINO ACIDS AND INTERMEDIATES USED IN SAID PROCESS Royal College of Surgeons in Ireland (IE) 2014-10-01 EP disclosed
WO-2013189978-A1 PROCESS FOR PREPARING ß-AMINO ACID DERIVATIVES AND USE OF SAID PROCESS FOR PREPARING TELAPREVIR SANDOZ AG (CH) 2013-12-27 WO disclosed
WO-2013076225-A1 PROCESS FOR THE PREPARATION OF GAMMA AMINO ACIDS AND INTERMEDIATES USED IN SAID PROCESS ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) 2013-05-30 WO disclosed
US-20110172438-A1 Enantioselective Cascade Michael-Michael Reactions and Related Catalysts NATIONAL SCIENCE FOUNDATION 2011-07-14 US disclosed
WO-2010027510-A2 ENANTIOSELECTIVE CASCADE MICHAEL-MICHAEL REACTIONS AND RELATED CATALYSTS STC. UNM (US) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172438-A1 Enantioselective Cascade Michael-Michael Reactions and Related Catalysts FASN, PTGES, CBS CYP2D6 1882/4885CYP1A2 623/4885CYP2C19 856/4885
US-11512041-B2 Highly enantioselective access to cyclic beta-amino acids BCAT1, BCAT2, SLC7A1 CYP2D6 1188/4885CYP1A2 721/4885CYP2C19 1043/4885
US-20210171436-A1 HIGHLY ENANTIOSELECTIVE ACCESS TO CYCLIC BETA-AMINO ACIDS BCAT1, BCAT2, SLC7A1 CYP2D6 1188/4885CYP1A2 721/4885CYP2C19 1043/4885
US-20160229778-A1 DIRECT B-ARYLATION OF CARBONYL COMPOUNDS DBH, DDT, CBR3 CYP2D6 103/4885CYP1A2 310/4885CYP2C19 781/4885
US-20140336412-A1 PROCESS FOR THE PREPARATION OF GAMMA AMINO ACIDS AND INTERMEDIATES USED IN SAID PROCESS GLRB, GABRP, GABRG1 CYP2D6 70/4885CYP1A2 123/4885CYP2C19 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.